GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.02
-0.04 (-0.05%)
At close: 4:00PM EST

79.52 +0.50 (0.63%)
Pre-Market: 4:00AM EST

Stock chart is not supported by your current browser
Previous Close79.06
Open79.34
Bid79.42 x 300
Ask80.10 x 200
Day's Range78.65 - 79.40
52 Week Range63.76 - 86.27
Volume6,366,180
Avg. Volume8,222,619
Market Cap103.221B
Beta0.87
PE Ratio (TTM)8.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (2.63%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes19 hours ago

    Gilled, CVS And Two Other Stocks Down But Not Out

    These stocks have been wounded but should recover.

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist19 hours ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist21 hours ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit22 hours ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist22 hours ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist4 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.

  • 2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
    Motley Fool4 days ago

    2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better

    In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • 3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher
    InvestorPlace4 days ago

    3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher

    Pfizer Inc. (NYSE:PFE) has been rather quietly churning higher. Over the last six months, Pfizer stock is up nearly 10% and it hit new highs in December. With a dividend yield of 3.75% and a low valuation, many investors are content holding shares of PFE.

  • Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward
    Market Realist5 days ago

    Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward

    In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.

  • Barrons.com5 days ago

    New Year, New Gilead? It's No Longer Just About Hepatitis C

    Gilead Sciences (GILD) is changing its stripes. BMO Capital Markets' M. Ian Somaiya, for one contends that the stock is more "intriguing" as its focus shifts away from anti-virals. Somaiya argues that more predictable HCV sales, along with a strong launch of its HIV treatment bictegravir and non-Hodgkin lymphoma drug Yescarta are crucial for Gilead's new, more diverse, identity.

  • What Does Teva’s Recently Announced Restructuring Plan Entail?
    Market Realist5 days ago

    What Does Teva’s Recently Announced Restructuring Plan Entail?

    On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.

  • Can Biotech Keep Last Year's Momentum Alive in 2018?
    Zacks5 days ago

    Can Biotech Keep Last Year's Momentum Alive in 2018?

    The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

  • TEVA Stock Price Rises on Generic Launch of Viread
    Market Realist5 days ago

    TEVA Stock Price Rises on Generic Launch of Viread

    Key Updates from Teva Pharmaceuticals at the Start of 2018

  • How Akcea Therapeutics’ Volanesorsen Performed in 3Q17
    Market Realist5 days ago

    How Akcea Therapeutics’ Volanesorsen Performed in 3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • Big Pharma CEOs Speak About Impact of Tax Reform on M&A
    Zacks5 days ago

    Big Pharma CEOs Speak About Impact of Tax Reform on M&A

    This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

  • Teva’s Launch of Generic Version of Reyataz Boosts Stock
    Market Realist5 days ago

    Teva’s Launch of Generic Version of Reyataz Boosts Stock

    On December 27, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of Reyataz, which is a registered trademark of Bristol-Myers Squibb (BMY) in the United States. The generic version of Reyataz is Teva’s fifth generic drug offering in the area of HIV-1 infection treatment. In fiscal 3Q17, the total generic products sales contributed approximately 54% to the company’s total sales as compared to 59% of the generics sales contribution in fiscal 3Q16.

  • How Ionis’s Spinraza Performed in 3Q17
    Market Realist5 days ago

    How Ionis’s Spinraza Performed in 3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • How Mylan’s Europe Segment Performed in 3Q17
    Market Realist5 days ago

    How Mylan’s Europe Segment Performed in 3Q17

    Who’s Watching Mylan in January 2018?

  • InvestorPlace5 days ago

    Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk

    Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce a heavy debt burden.

  • Exploring Ionis’s 3Q17 Quarterly Revenue Trend
    Market Realist6 days ago

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.

  • How Mylan’s North America Segment Performed in 3Q17
    Market Realist6 days ago

    How Mylan’s North America Segment Performed in 3Q17

    Who’s Watching Mylan in January 2018?

  • Investopedia6 days ago

    Gilead's Breakout May Spark 18% Gain

    From a technical standpoint, Gilead's stock appears to be on the verge of a major breakout.

  • 5 Ways Gilead Sciences Plans to Return to Growth
    Motley Fool7 days ago

    5 Ways Gilead Sciences Plans to Return to Growth

    Gilead's CEO reveals the biotech's game plan at the J.P. Morgan Healthcare Conference.